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Purpose: Antipsychotic monotherapy is often recommended over antipsychotic polypharmacy 
because of fewer adverse events, reduced treatment complexity, and lower medication cost. This 
study compared the rate and the duration of antipsychotic monotherapy following initiation of 
olanzapine or risperidone in the treatment of outpatients with schizophrenia in Japan.
Methods: Outpatients diagnosed with schizophrenia in the Japan Medical Data Center 
database were identified using International Statistical Classification of Diseases and Related 
Health Problems, 10th Revision, diagnosis codes. Patients were between 20 and 65 years 
old, initiated on olanzapine or risperidone therapy between August 2003 and July 2008, and 
  continuously enrolled during the 6 months prior to and the 12 months following the initiation 
date.   Antipsychotic polypharmacy was defined as concurrent use of two or more   antipsychotics. 
The probability of monotherapy during the 12-month follow-up period was assessed using a 
propensity score-adjusted generalized estimating equation model. Duration of monotherapy 
was contrasted using a propensity score-adjusted bootstrapping model.
Results: After applying all inclusion and exclusion criteria, the final analytic sample consisted 
of 332 olanzapine- and 496 risperidone-treated outpatients. At treatment initiation, 61.5% of the 
olanzapine-treated patients and 45.6% of the risperidone-treated patients received antipsychotic 
monotherapy (P , 0.001). After correcting for background differences, monotherapy was more 
common among olanzapine-treated patients (P = 0.001). In addition, olanzapine was used as 
monotherapy for a longer duration (P = 0.006).
Conclusion: Consistent with prior global research, this retrospective naturalistic study of 
schizophrenia outpatients in Japan found that olanzapine is more likely to be used as monotherapy 
and to be used as monotherapy for a longer duration than risperidone.
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Introduction
Antipsychotic medications have been a core treatment modality for patients with 
schizophrenia over the past 40 years, with antipsychotic monotherapy considered 
the treatment of choice.1 Despite consistent recommendations for antipsychotic 
monotherapy, antipsychotic polypharmacy, the concomitant use of two or more 
antipsychotics, is commonplace in the treatment of schizophrenia.2–7 Antipsychotic 
polypharmacy seems to be increasing over time as additional antipsychotic treatment 
options become available.8,9
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Antipsychotic polypharmacy appears to be used to 
improve efficacy after partial response or nonresponse to 
monotherapy,10,11 but these clinical benefits have not been 
clearly documented.4,7,12,13 However, the disadvantages 
are clear: antipsychotic polypharmacy has a higher risk of 
adverse events and potential drug–drug interactions;11 it 
increases complexity, making assessment of the medication 
regimen and management of future symptom exacerbations 
more difficult;14 and it increases antipsychotic treatment costs 
at a time of growing budget constraints.14–19
The prevalence of antipsychotic polypharmacy has 
been reported to range between 13% and 70%, depending 
on the study population, country, year, methodology, and 
duration.6,7,20–26 A prospective, observational, noninterven-
tional study in the United States (US)27 found that over a 
12-month period, 58% of the patients had at least one period 
of antipsychotic polypharmacy lasting 60 consecutive days 
or longer. The rate of antipsychotic polypharmacy has been 
found to be higher in Japan than in the US.28 A Japanese 
national cross-sectional survey of 9325 inpatients with 
schizophrenia revealed that 67%–70% were treated with 
more than one antipsychotic, and 75.6% of those treated 
with an atypical antipsychotic were also treated with another 
antipsychotic.25,26 The very high rate of antipsychotic poly-
pharmacy has led the Japanese Ministry of Health, Labour 
and Welfare to reward physicians who reduce their patients’ 
atypical antipsychotic polypharmacy.
Prior research has identified multiple factors that predict 
antipsychotic polypharmacy use. Antipsychotic polyphar-
macy has been associated with greater illness severity, longer 
illness duration, comorbid depression, and treatment with 
typical antipsychotics, as well as the use of certain atypical 
antipsychotics.4,7,10 The rate and duration of antipsychotic 
polypharmacy differs among atypical antipsychotics,7 
with olanzapine-initiated patients more likely to be treated 
with monotherapy than those treated with other atypical 
antipsychotics.16,23,27,29–32 Prior research has shown a higher 
rate and a longer duration of antipsychotic monotherapy 
with olanzapine than risperidone in the treatment of patients 
with schizophrenia in the US27 and in Europe.32 However, it 
is unclear whether these prior findings can generalize across 
world geographies, especially to the Japanese health care 
system, where antipsychotic polypharmacy appears to be 
highly prevalent.
The objective of the current retrospective claims database 
analysis is to assess the rate and duration of antipsychotic 
polypharmacy among outpatients in Japan who were initiated 
on olanzapine or risperidone for the treatment of   schizophrenia. 
Olanzapine and risperidone are the two most frequently used 
atypical antipsychotics for schizophrenia in Japan.33
Methods
Data source
This study utilized the Japan Medical Data Centre Database 
(JMDC), an employment-based administrative database con-
taining the medical and pharmacy claims from ten different 
payers (insurance societies). The JMDC included information 
on approximately 0.6 million employed individuals or their 
family members who were enrolled between August 2003 
and July 2009.
The JMDC consisted of inpatient, outpatient, and 
pharmacy administrative claims. The medical claims 
(inpatient and outpatient) included basic demographics, 
diagnoses, procedures, and fees. Diagnoses were specified 
with International Statistical Classification of Diseases and 
Related Health Problems, 10th Revision (ICD-10), diagnosis 
codes.34 For the medical claims, the date of service information 
was restricted to month and year. Pharmacy claims included 
the full dispensing date, the days of supply, and dosage 
information. Drugs were classified using the Anatomical 
Therapeutic Chemical Classification System codes.35
Sample selection
The initial extract of data from the JMDC database included 
the administrative claims between August 2003 and 
July 2009 for patients who had at least one diagnosis of 
schizophrenia (F20.0–F20.9). This initial data cut included 
4861 individuals.
The primary selection criterion for this analysis was the 
initiation of either olanzapine or risperidone (ie, index drug) 
before June 30, 2008. Based on each patient’s first phar-
macy claim for the index drug, an index date was   identified. 
  Initiation was defined as a period of 3 months without a 
claim for the index drug prior to the index date. Patients were 
categorized into two mutually exclusive study cohorts based 
on the most recent initiation: risperidone or olanzapine.
The study period varied for each patient and included the 
6 months preceding and the 12 months following the index 
date. The study period was divided into a baseline period 
and a treatment period, with the index date marking the first 
day of the treatment period.
Additional inclusion and exclusion criteria included the 
following: (1) patients were required to have at least one 
diagnosis of schizophrenia (F20.0–F20.9) during the study 
period; (2) patients were excluded from the study if they had 
ICD-10 diagnoses for any of the following conditions during 
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the study period: organic mental disorders, organic brain 
disorders, dementia, or Alzheimer’s disease; (3) patients 
were excluded from the analysis if they did not have at least 
one claim prior to and one claim after the study period (this 
was used as a proxy for continuous enrollment); (4) the 
analysis was restricted to individuals who were between 20 
and 65 years of age (the lower cutoff was used to restrict the 
population to adults and the upper cutoff was used because 
of potential eligibility for Health Insurance for the Elderly); 
(5) finally, individuals who were inpatients at the time of the 
index date were excluded from the analysis.
Outcome measures
Past observational research has differentiated   antipsychotic 
monotherapy from antipsychotic polypharmacy in   multiple 
ways.27 The simplest definition of antipsychotic   polypharmacy 
is the use of two or more antipsychotics on any given day. 
  Unfortunately, this elegant definition also includes cross-
tapering and “as needed” use. A more restrictive definition is 
the concurrent use of two or more antipsychotics for at least 
60 days.27 This restrictive definition eliminates cross-tapering 
and “as needed” use, but it also excludes any short-term 
polypharmacy.
The primary outcome variable in this study was the propor-
tion of patients treated with monotherapy across each day of 
the treatment period. The second outcome variable, duration 
of monotherapy, was defined as the number of days of anti-
psychotic monotherapy use from the index date to the end of 
the study. The final outcome variable was defined as the time in 
days from the index date to the first day of a period of persistent 
antipsychotic polypharmacy (60+ days). The first two outcome 
variables use a simple definition of polypharmacy while also 
incorporating time and the third outcome variable captures 
only the more restrictive   definition of polypharmacy.
Baseline measures
All analyses were adjusted for baseline differences between 
patients initiated on olanzapine and patients initiated on 
  risperidone. The baseline variables were calculated from infor-
mation available during the 6 months prior to the index date.
The Anatomical Therapeutic Chemical Classification 
System codes from the pharmacy claims were used to create 
indicator (yes/no) variables for baseline treatment with several 
relevant classes of drugs. Atypical antipsychotics were defined 
as olanzapine, risperidone, aripiprazole, blonanserin, clozapine, 
perospirone, quetiapine, and zotepine. Anticholinergic/
antiparkinsonian drugs included amantadine, biperiden, 
levodopa, carbidopa-levodopa, selegiline, and trihexyphenidyl. 
Antidepressants included amoxapine, setiptiline, trimipramine, 
mirtazapine, amitriptyline, imipramine, clomipramine, 
trazodone, dosulepin, nortriptyline, maprotiline, mianserin, 
lofepramine, milnacipran, fluvoxamine, sertraline, and 
paroxetine. Hypnotics/sedatives included amobarbital, 
secobarbital, barbital, phenobarbital, pentobarbital, passiflora, 
estazolam, quazepam, zopiclone, triazolam, trichloroethyl, 
nitrazepam, nimetazepam, haloxazolam, flunitrazepam, 
flurazepam, brotizolam, bromvalerylurea, lormetazepam, 
rilmazafone, zolpidem, and chloral hydrate. The final baseline 
pharmacy variables were an indicator variable for prior use 
of risperidone and a second indicator variable for prior use 
of olanzapine.
Baseline comorbidities were identified using the ICD-10 
diagnostic codes. Indicator variables for the following comor-
bid conditions were coded: depression (F32, F33), manic 
episodes (F30), and diabetes mellitus (E10–E14).
Any physician the patient consulted could have written 
the initial prescription for the index drug (olanzapine or 
risperidone). If the physician was identified as a psychiatrist 
in the administrative claims, the index drug was considered 
“psychiatrist prescribed.”
Health care utilization variables were created to capture 
the costs and resources used by patients during the baseline 
period. Outpatient visits were measured as a count of the 
number of outpatient visits. Inpatient service utilization 
was coded as present or absent. Antipsychotic adherence 
was designated if a patient had filled scripts for any anti-
psychotic on 80% or more of the days in the baseline period 
(ie, medication possession ratio $0.80). Finally, total health 
care costs were aggregated for the baseline period, based on 
the amounts paid by the health plans for medical services 
and medication prescriptions.
Statistical methods
Univariate comparisons of baseline characteristics between 
patients initiated on olanzapine or risperidone were con-
ducted using chi-square tests or Fisher’s exact tests for 
categorical variables and Student’s t-tests or Wilcoxon 
rank-sum tests for continuous variables. A propensity score 
predicting the probability of initiating treatment with olan-
zapine or risperidone was calculated using logistic regression 
with the baseline variables. Balance between the treatment 
groups on each baseline characteristic after adjusting for the 
propensity score was verified using analysis of variance for 
continuous variables and logistic regression for categorical 
variables. Table 1 contains each of the variables used in the 
propensity score calculation.
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In each of the outcome models, the propensity score was 
included as a covariate to adjust for background   difference. 
The probability of monotherapy across the 12-month 
outcome period was estimated using a repeated-measures 
generalized estimating equation model with a logit link 
function, an autoregressive error structure, and a binomial 
error distribution. This model included terms for treatment 
(olanzapine or risperidone), time (in days), the treatment-by-
time interaction, and the propensity score.
Duration of monotherapy was a positively skewed 
variable; therefore, a nonparametric, propensity score bin 
bootstrapping resampling approach was used to test dif-
ference in duration between olanzapine and risperidone. 
Finally, survival analyses compared the time to persistent 
polypharmacy between olanzapine- and risperidone-initiated 
patients. The time to persistent polypharmacy was compared 
using the Kaplan-Meier method with a log-rank test and 
a Cox proportional hazards model that also included the 
propensity score. Survival curves were constructed from 
unadjusted Kaplan-Meier estimates. In the survival analyses, 
patients were censored (no longer eligible to be considered 
for a “treated with persistent antipsychotic polypharmacy” 
event) if they discontinued the index drug for a period of 30 
or more days or if they completed the full 12-month study 
period with monotherapy. The significance level was set 
at α = 0.05 for all hypothesis tests and all analyses were 
Table 1 Baseline characteristics for olanzapine and risperidone initiators
Variable Olanzapine (n = 332) Risperidone (n = 496) P-value
Demographics
  Age (years) [mean (SD)] 36.5 (9.8) 37.2 (10.6) 0.35
  gender (male) [n (%)] 163 (49.1) 234 (47.2) 0.59
Prior resource use
  Inpatient service use [n (%)] 27 (8.1) 46 (9.3) 0.57
  Outpatient visits [mean (SD)] 16.0 (14.4) 16.4 (17.0) 0.68
  Total treatment cost (¥) [mean (SD)] 208,894 (335,316) 235,500 (340,121) 0.77
  Antipsychotic adherence [n (%)] 95 (28.6) 171 (34.5) 0.08
Prior comorbidities
  Diabetes [n (%)] 36 (10.8) 79 (15.9) 0.04
  Depression [n (%)] 158 (47.6) 218 (44.0) 0.30
  Manic episode [n (%)] 197 (59.3) 254 (51.2) 0.02
Prior medication use
  Atypical antipsychotic use [n (%)] 145 (43.7) 237 (47.8) 0.25
  Typical antipsychotic use [n (%)] 106 (31.9) 184 (37.1) 0.13
  Olanzapine use [n (%)] 52 (15.7) 92 (18.5) 0.28
  Risperidone use [n (%)] 75 (22.6) 117 (23.6) 0.74
  Antipsychotic polypharmacy use [n (%)] 44 (13.3) 90 (18.1) 0.06
  Antidepressant use [n (%)] 188 (56.6) 215 (43.3) ,0.001
  Hypnotics/sedative use [n (%)] 183 (55.1) 270 (54.4) 0.85
  Anticholinergic use [n (%)] 69 (20.8) 135 (27.2) 0.04
  Psychiatrist prescribed [n (%)] 134 (40.4) 186 (37.5) 0.41
Abbreviation: SD, standard deviation.
1. Schizophrenia diagnosis
Olanzapine or risperidone initiators
prior to June 2008
Olanzapine
1198 2010
1075
984
543
484
332 496
664
827
1560
1744
Risperidone
3. Continuous enrollment
2. No organic mental illness or
    dementia diagnoses
4. Age between 20 and 65 years
5. Outpatient at time of medication
     initiation
Figure 1 Patient selection. The diagram displays the number of olanzapine and 
risperidone initiators remaining after each of the inclusion and exclusion criteria 
were applied. The continuous enrollment criteria required each patient to have at 
least one claim prior to and following the study period.
conducted using SAS software (v 9.1.3; SAS Institute Inc, 
Cary, NC).
Results
Figure 1 displays a flow diagram for the olanzapine- and 
  risperidone-treatment cohorts following the application of 
each inclusion and exclusion criteria. Nearly two-thirds 
(63.7%) of the individuals with schizophrenia in the 
initial JMDC data had at least one pharmacy claim for 
olanzapine or risperidone. After applying all inclusion and 
exclusion criteria, the final analytic sample consisted of 
828   individuals – 332 were treated with olanzapine and 
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496 treated with   risperidone. The average age of the patients 
in the final sample was 36.9 years, and 48.0% were male.
Table 1 provides the baseline demographic characteristics, 
prior health care resource use, prior medical and psychiat-
ric comorbidities, and prior medication use and univariate 
comparison between the olanzapine and risperidone cohorts. 
The risperidone initiators were more likely to have prior 
claims with diagnoses for diabetes mellitus and prior use of 
anticholinergic drugs. The olanzapine initiators were more 
likely to have prior claims with diagnoses for manic episodes 
and prior antidepressant use. The C-statistic for the logistic 
regression used to calculate the propensity score from all of 
the characteristics in Table 1 was 0.608, indicating that the 
model could accurately discriminate a randomly selected 
risperidone-treated individual from a randomly selected 
olanzapine-treated individual 60.8% of the time.
On the index date, 61.5% of the olanzapine-initiated 
patients and 45.6% of the risperidone-initiated patients were 
treated with antipsychotic monotherapy (P , 0.001). For the 
patients who were treated with antipsychotic polypharmacy, 
Table 2 lists the antipsychotics that were used as initial 
polypharmacy with olanzapine or risperidone.
Figure 2 displays the percent of olanzapine and ris-
peridone initiated patients who were treated with antipsy-
chotic monotherapy during the 12-month treatment period. 
Table 3 gives the results of the generalized estimating equa-
tion model, comparing the rates of monotherapy over time 
after adjusting for baseline differences. Across the 12-month 
treatment period, olanzapine-treated patients were more 
likely to be treated with monotherapy than risperidone-treated 
patients, and the rates of monotherapy increased over time 
for both treatment groups.
The mean (plus or minus the standard deviation) duration 
of monotherapy was 116.6 ± 130.6 days for the olanzapine-
treated patients and 92.8 ± 123.0 days for the risperidone-
treated patients (P = 0.008). The propensity score-adjusted 
bootstrapping model showed that olanzapine-treated patients 
were treated with monotherapy for 22.2 (95% confidence 
interval: 5.0, 39.8) days longer than risperidone-treated 
patients (P = 0.006).
Finally, a time-to-event model was used to contrast 
the time to persistent polypharmacy for olanzapine- and 
risperidone-initiated patients. Figure 3 gives the Kaplan-
Meier estimates of the proportion of patients remaining 
on monotherapy across the 12-month study period. In a 
Cox proportional hazards model, adjusting for background 
differences using the propensity score, the hazard ratio for 
antipsychotic polypharmacy use in the olanzapine-treated 
patients relative to risperidone-treated patients was 0.72 
(95% confidence interval: 0.54, 0.97; chi-square = 4.71; 
P , 0.03). The hazard ratio indicates the odds were 0.72 that 
an olanzapine-treated patient would utilize polypharmacy 
before a risperidone-treated patient.
Discussion
Consistent with prior observational research in Japan, antipsy-
chotic polypharmacy was common in this naturalistic sample 
of outpatients with schizophrenia. A univariate analysis 
showed that the patients treated with olanzapine (61.5%) were 
more likely to be initiated on antipsychotic monotherapy than 
those treated with risperidone (45.6%, P , 0.001). When 
adjusting for background characteristics and examining the 
Table 2 Initial concomitant antipsychotic treatment
Antipsychotic Olanzapine Risperidone
n %* n %*
Aripiprazole 30 9.0 55 11.1
Haloperidol 23 6.9 42 8.5
Olanzapine N/A N/A 59 11.9
Quetiapine 15 4.5 19 3.8
Levomepromazine 10 3.0 17 3.4
Risperidone 18 5.4 N/A N/A
Chlorpromazine/promethazine/ 
phenobarbital
5 1.5 12 2.4
Chlorpromazine hydrochloride 2 0.6 8 1.6
Zotepine 3 0.9 12 2.4
Sulpiride 4 1.2 8 1.6
Bromperidol 2 0.6 9 1.8
Perospirone 5 1.5 5 1.0
Other antipsychotics 11 3.3 24 4.8
Note: *Denominators for the percentages were 332 for the olanzapine cohort and 
496 for the risperidone cohort.
Abbreviation: N/A, not applicable.
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Figure 2 Percentage of patients treated with monotherapy during the 12 months 
following initiation of olanzapine or risperidone. The generalized estimating equation 
model showed that, after correcting for baseline characteristics, patients initiated 
on olanzapine were significantly more likely to be treated with monotherapy across 
the 12-month treatment period (P = 0.001) and the rate of monotherapy increased 
over time (P , 0.001).
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probability of antipsychotic monotherapy across the full 
12-month study period, the patients treated with olanzapine 
were significantly more likely to be treated with monotherapy 
(odds ratio [OR] = 1.62) and the rate of monotherapy increased 
over time for both treatment groups. Additionally, the dura-
tion of antipsychotic monotherapy was significantly longer 
for olanzapine- than risperidone-treated patients. In Japan, 
where antipsychotic polypharmacy is particularly common 
in the treatment of schizophrenia, olanzapine treatment was 
associated with a significantly greater rate and a longer dura-
tion of monotherapy than risperidone treatment.
Greater use of antipsychotic monotherapy for patients 
using olanzapine than risperidone has previously been 
found in naturalistic studies outside of Japan.27,32 In a large 
observational study in the US, olanzapine was found to 
be significantly (OR = 1.36) more likely to be used as 
monotherapy than risperidone and for a significantly longer 
duration (21.5 days longer; 252.1 vs 230.6 days).27 The dif-
ference in duration found in the current study (22.5 days 
longer) was very similar. In the Pan-European Schizophrenia 
Outpatient Health Outcomes study, the odds of monotherapy 
for olanzapine treatment relative to risperidone were 1.56, 
remarkably similar to the current study (OR = 1.62), with 
significantly more days of monotherapy for olanzapine- than 
risperidone-treated patients (272 vs 261 days).32 The findings 
in the current Japanese study replicate the findings previ-
ously reported in the US and Europe. However, the duration 
of monotherapy was shorter in this Japanese study (116.6 
and 92.8 days for olanzapine and risperidone, respectively), 
which is consistent with prior research reporting more fre-
quent use of polypharmacy in Japan.36
The finding that olanzapine was associated with greater 
antipsychotic monotherapy use was not unanticipated, 
considering that antipsychotic polypharmacy may be imple-
mented to bolster medication efficacy.10,11 A meta-analysis 
of 78 studies with 13,558 participants found olanzapine to 
confer significantly greater efficacy than other atypicals, 
including risperidone, in the treatment of schizophrenia.37 
The results of this meta-analysis were rather robust with 
regard to the effects of industry sponsorship, study quality, 
dosages, and trial duration. Greater effectiveness of olanzap-
ine than risperidone in the treatment of schizophrenia offers 
a potential explanation of the current findings. However, the 
reasons physicians chose to use antipsychotic monotherapy 
or polypharmacy for each patient could not be specifically 
examined in this claims database study. Physicians may 
prefer to use risperidone as polypharmacy because of other 
properties of the medications or for patients presenting with 
a specific set of symptoms.
Limitations
Administrative claims data are collected for reimburse-
ment rather than clinical purposes, thus the accuracy and 
level of detail are limited. Many conditions are not coded 
in claims and some comorbid conditions might have been 
  underdiagnosed. The percentage of patients with claims for 
diabetes mellitus was higher than the 8.6% prevalence rate 
reported for patients with schizophrenia in Japan from past 
chart review research.38 Diabetes mellitus diagnoses may 
be coded on a claim any time a blood test (ie, HbA1c) is 
conducted, regardless of the status of the results, leading to 
the potential for overdiagnosis.
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Figure  3  Time  to  persistent  antipsychotic  polypharmacy  for  olanzapine-  and 
risperidone-initiated patients. The log-rank test indicated that olanzapine patients 
had  a  significantly  longer  time  to  persistent  polypharmacy  (P  =  0.002)  than 
risperidone patients.
Table 3 Results of generalized estimating equation model predicting probability of monotherapy over the 12-month study
Effect Estimate 95% CI OR χ2 P-value
Antipsychotic (olanzapine) 0.483 0.203, 0.763 1.621 11.55 ,0.001
Time (days) 0.0012 0.0005, 0.0019 1.0012 9.73 0.002
Antipsychotic* time (days) -0.0006 -0.0018, 0.0007 0.9994 0.75 0.386
Propensity score -4.960 -6.469, -3.450 0.007 44.89 ,0.001
Notes: *The antipsychotic effect indicated the odds of olanzapine being used as monotherapy was 1.621 times higher than risperidone. The time effect indicates that 
monotherapy use increased over each day in the follow-up period. The non-significant antipsychotic-by-time interaction indicated that the difference between olanzapine and 
risperidone did not change over time more than was expected by chance.
Abbreviations: χ2, chi-square; CI, confidence interval; OR, odds ratio.
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Retrospective analyses of administrative claims data allow 
for the unobtrusive observation of usual clinical care at the 
cost of experimental control. Patients were not randomized to 
olanzapine or risperidone. Although propensity scores were 
used to adjust for multiple background variables, differences 
between olanzapine- and risperidone-initiated patients on vari-
ables not collected in this database could still bias the results. 
For instance, physician characteristics and preferences were not 
available to be included in the propensity score model. Finally, 
because the administrative data contained claims only for 
employees or their families, the sample was younger and might 
not be representative of the Japanese population as a whole.
Conclusion
Consistent with prior global research, this retrospective 
naturalistic study of outpatients with schizophrenia in Japan 
found that olanzapine is more likely than risperidone to be 
used as monotherapy and for a longer duration. Antipsychotic 
monotherapy is consistently recommended over polyphar-
macy because of reduced complexity, reduced risk of adverse 
events, reduced risk of drug interactions, and reduced total 
cost of drug therapy.
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